

# SUBJECT INDEX

- Abl*, glucose transport regulation by IL-3 and oncogenes and, 387
- ACE N-domain, structure-function studies of *N*-acetylseryl-aspartyl-lysyl-proline and, 611
- N*-Acetylseryl-aspartyl-lysyl-proline, N-domain selectivity of angiotensin I-converting enzyme and, 611
- Activator protein-1,  $\beta$ -lapachone suppression of, 763
- Acylfulvene, metabolism in rat liver cytosol, 83
- Adenosine A<sub>2A</sub> receptors, species differences in human and rat, 65
- Adenosine 3',5'-cyclic monophosphate (cAMP)
  - P<sub>1</sub> receptors influence on forskolin effects in PC12 cells, 355
  - receptors, human *vs.* rat, 65
- Adenovirus, attachment and internalization, receptors mediating, 975
- Adenylyl cyclase, prostaglandins role in inhibition of, 851
- Adrenal cortical oxygenation, dehydroepiandrosterone sulfate and, 329
- Adrenal glomerulosa cells, ruthenium red inhibition of, rats, 209
- $\beta$ -Adrenergic agonist, neurotensin and, effects on cAMP accumulation and DNA synthesis in prostate cancer, 1391
- Adriamycin
  - antitumor effects, mechanisms of action of, 727
  - cardiomyopathy induced by, cytochrome c oxidase II gene expression suppression and, 481
  - MCF-7 cells resistant to, Ah receptor loss in, 1253
- Affinity, glucose transport regulation by IL-3 and oncogenes and, 387
- Aging
  - advanced glycation end products and, 303
  - dehydroepiandrosterone sulfate and, 329
  - iron deprivation as therapy and, 1345
- Ah receptor, loss in benzo[ $\alpha$ ]pyrene- and adriamycin-resistant MCF-7 cells, 1253
- Albumin, succinylated human serum, mechanism of anti-HIV activity of, 889
- Alcohol dehydrogenase, sex-dependent induction, rats, 1067
- Aldehyde dehydrogenase, liver cytosolic, retinoic acid synthesis and, 195
- Aldosterone, production in rat adrenal glomerulosa cells, ruthenium red effects on, 209
- Allometry, predicting blood ethanol elimination and, in mammals, 219
- Allosteric modulation, muscarinic receptors and, 171
- Alloxan, insulin release modulation in INS-1 cells exposed to, 639
- All-*trans*-retinoic acid, prenatal biosynthesis inhibition by ethanol and lipid peroxidation reactions, 811
- Alminoprofen, mechanisms of action of, 433
- Alveolar macrophages, chloroquine administration effects on oxidative responses by, 907
- Alzheimer's disease
  - advanced glycation end products and, 303
  - NF- $\kappa$ B/Rel protein role in signaling pathways in, 1
- 3-Aminobenzamide, DNA damage in colon cancer cells and, 19
- Aminoguanidine
  - PTB mechanism of action and, 303
  - time-dependent production of nitric oxide by hepatocytes and, rats, 1223
- 3-Aminopropylphosphonate, tumor pH in breast cancer xenografts, MRS investigation of, 309
- Amyotrophic lateral sclerosis, glial cell line-derived neurotrophic factor gene therapy and, 135
- Analog II, breast cancer cell apoptosis and, 97
- Angiotensin I-converting enzyme, N-domain selectivity of, structure-function studies assessment of, 611
- Angiotensin II
  - epidermal growth factor and, regulation of extracellular signal-regulated protein kinase and, effects on mitogenesis, 425
  - receptor, internalization and signaling in rat hepatocytes, 1125
- Anion channel, volume-sensitive, pancreatic  $\beta$ -cell function studies and, 583
- Anionic phospholipids, mithramycin membrane interaction with, 981
- Anthracycline
  - antitumor effects, mechanisms of action of, 727
  - disaccharides, sugar moiety role in pharmacologic activity of, 1133
  - prodrugs, daunorubicin-GA3 distribution and pharmacokinetics in ovarian cancer xenografts, 673
- Antiallergic agents, oxatomide, influence on membrane structures, 503
- Antibiotics
  - antitumor, mithramycin membrane interaction with anionic phospholipid vesicles, 981
  - epithelial peptide, clinical studies of, 121
- Anticancer agents, epidermal growth factor receptor inhibition by CL-387,785, 917
- Antidepressant drugs, apoptosis induced by, reactive oxygen species generation in mitochondrial membrane potential during, 1199
- Anti estrogen binding site, cell cytotoxicity and, 657
- Antihypertensive agents, SKP-450, biochemical basis for, 579
- Anti-inflammatory drugs, nonsteroidal: *see* Nonsteroidal anti-inflammatory drugs
- Antimicrobial peptides, epithelial, clinical studies of, 121
- Antineoplastic agents
  - gemcitabine resistance to cytosine arabinoside-resistant leukemia cell lines, 397
  - thiopene, toxicity in renal carcinoma cell lines, 1283
- Antioxidants
  - ebfelen protective effects against cytotoxicity and DNA damage in HepG<sub>2</sub> cells, 273
  - fluvastatin sodium protective effects on oxidative modification of low-density lipoproteins and, 697
  - virgin olive oil effects in leukocytes, 445

## Antitumor agents

- acylfulvene, metabolism in rat liver cytosol, 83
- adriamycin, cardiovascular toxicity of, 481
- adriamycin and daunorubicin, mechanisms of action of, 727
- Analog II, breast cancer cell apoptosis and, 97
- apoptosis induced by, thymosin  $\beta_4$  levels in, 1105
- gemcitabine and etoposide, effects in non-small cell lung and ovarian cancer, 407
- limonene, protein prenylation inhibition by, 801
- mithramycin, membrane interaction with anionic phospholipid vesicles, 981
- naphthoquinones effects in colon cancer cell lines, 27
- tetrazepinone, mechanism of action in ovarian cancer cell line, 753

## Apoptosis

- antitumor agent-induced, thymosin  $\beta_4$  levels in, 1105
- breast cancer cell,  $A_{II}$  effects, 97
- chemically induced, of HL-60 cells, hydrogen peroxide and hydroxyl radical involvement in, 1361
- DMSO role in promoting, 39
- intracellular localization of Bax protein and, 143
- $\beta$ -lapachone suppression of, 763
- NF- $\kappa$ B/Rel protein in cancer treatment and, 9
- NF- $\kappa$ B/Rel proteins role in signaling pathways and, 1
- NPM-translocation and, daunomycin effects on, 1265
- oxidative stress-induced, ascorbic acid role in inhibition of, in leukemia cells, 823
- paclitaxel-induced, mechanisms of, 1215
- reactive oxygen intermediates as mediators of, 231

## Aporphine alkaloids, topoisomerase II inhibition by, 1141

## Ara-C, gemcitabine activity in resistance to, 397

## Arachidonic acid

- N*-ethylmaleimide-stimulated, release in platelets, 785
- prostaglandin H synthase inhibition and 12-lipoxygenase activity by, 631

## 2-Arachidonoylglycerol, hydrolysis by brain enzymes, 417

## Arbutin, methyl gentisate evaluation as skin-lightening agent and, 663

## Arteriosclerosis

- dehydroepiandrosterone sulfate and, 329
- lovastatin effects on oxidized low-density lipoprotein receptor expression on vascular smooth muscle cells and, 383

## Aryl hydrocarbon receptor

- binding, primaquine effects, 255
- nuclear translocator, activation and repression domains of, rainbow trout, 1177

2-Arylpropionic acids,  $\beta$ -oxidation and oxidative phosphorylation inhibition by NSAIDs and, 837

## Ascorbic acid, oxidative stress-induced apoptosis and, in leukemia cells, 823

## Asialoglycoprotein receptor, expression in hepatocellular carcinoma, DNA synthesis inhibitors toxicity and, 793

## Aspirin, ubiquitin reaction with, NMR analysis, 1233

## Atrial natriuretic peptide receptors, isatin efficacy as antagonists of, 913

## Bacterial infection, lipopolysaccharide-induced, BPI effects on, 225

## Bactericidal/permeability-increasing protein (BPI), lipopolysaccharide-induced inflammatory response effects, 225

## Bax protein, intracellular localization of, subcellular fractionation analysis of, 143

## Bcl-2, paclitaxel-induced apoptosis and, 1215

## Behavior regulation, Fyn kinase and, molecular mechanisms, ethanol sensitivity and, 845

Benzo[ $\alpha$ ]pyrene

- MCF-7 cells resistant to, Ah receptor loss in, 1253
- mono- and diglucuronide formation from, by UDP-glucuronosyltransferase isoforms, 653

## Benzophenone, antiestrogen binding site and, 657

## Benzylphenoxy ethanamine, antiestrogen molecules, antiestrogen binding site influence on modification of, 657

## Binding sites, mechanism of anti-HIV activity of succinylated human serum albumin and, 889

## Bleomycin, toxicity, mechanisms of, 45

## Blood platelets, chlorpromazine and glycerolipid metabolism, 1113

## Blood-brain barrier

- permeability, hydroxypyridinones and, correlation between structure of, 1305

## ritonavir and P-glycoprotein inhibition and, 1147

## BPI: see Bactericidal/permeability-increasing protein

## Brain

- choline levels, *N*-methylnicotinamide influence on, 681
- ischemia-reperfusion, quercetin influence on nitric oxide level during, rats, 199

## mRNA expression of neurofilament subunits in, diisopropyl phosphorofluoridate-treated hens, 1245

## striatum, dopamine receptor activation in, rats, 155

## Breast cancer, tumor pH in xenografts, MRS investigation of, 309

Bromodeoxyuridine,  $A_{II}$ -induced cell death and, 97

## Bronchial epithelial cells, glucocorticoid pharmacologic characterization in, 1003

*tert*-Butyl hydroperoxide, hemoglobin and, oxidative stress induced by, effects on vascular smooth muscle cells, 989 $Ca^{2+}$  channels, inward current in *Xenopus* oocyte and, 491 ( $Ca^{2+}$ - $Mg^{2+}$ )-ATPase activity, calmodulin-stimulated, inhibition by DMSO, 39 $Ca^{2+}$  release channel, ryanodine receptor regulation by reactive nitrogen species and, 1079

## Caco-2 cells, naphthoquinone effects on, 27

## Calcium

- cytosolic, increase in platelets and macrophages, 263
- vascular endothelial cell activation by factor Xa and, 603

## cAMP: see Adenosine 3',5'-cyclic monophosphate

## Cancer: see also specific types

- histamine and polyamines involvement in, 1341

- [ $^3\text{H}$ ]norharman binding to ethanol-inducible cytochrome P450 2E1 in liver and, 511
- platelet-derived growth factor receptor tyrosine kinase inhibition and, 57
- Cancer cells, p53, Bax protein expression in nuclear membrane and, 143
- Cancer therapy
- gemcitabine and etoposide, effects, non-small cell lung and ovarian cancer, 407
  - NF- $\kappa\text{B}$ /Rel proteins and, 9
- Cannabinoid receptors, anandamide hydrolysis by brain enzymes and, 417
- $\beta$ -Carboline, [ $^3\text{H}$ ]norharman binding to ethanol-inducible cytochrome P450 2E1 in liver and, 511
- Carbon monoxide, cholinergic neuronal system modulation by dynorphin A (1–13) and, mice, 1321
- Carboxyfluorescein leakage, mithramycin membrane interaction with anionic phospholipid vesicles, 981
- Cardiomyopathy, adriamycin-induced, cytochrome c oxidase II gene expression suppression and, 481
- Cardioprotection, schisandrin role in, rats, 77
- Cardiovascular disease, platelet-derived growth factor receptor tyrosine kinase inhibition and, 57
- Carnitine palmitoyltransferase II, as control site for ketogenesis, 1011
- Catalase, overexpression of, HeLa cell sensitivity to cisplatin and, 545
- C3b, activated, rosmarinic acid attachment to, complement inhibition by, 1439
- $\beta$ -Cell activation, pancreatic, trioses in study of, 583
- Cell death, programmed, reactive oxygen intermediates as mediators of, 231
- Cell growth, thioredoxin and, selenium effects on, rats, 187
- Central nervous system dysfunction, *in utero* ethanol exposure and, 721
- Central nervous system infection, NF- $\kappa\text{B}$ /Rel protein role in signaling pathways in, 1
- Chagas' disease, enzymatic reduction studies of nitroheterocycles and, 549
- Chemokine receptors, HIV therapy, 451
- Chemotherapy
- anticancer, asialoglycoprotein receptor expression in hepatocellular carcinoma, DNA synthesis inhibitors toxicity and, 793
  - bleomycin internalization and toxicity, 45
  - combination, MRS investigation of tumor pH in breast cancer xenografts and, 309
  - glucosphingolipid synthesis slowing and, 589
- Chimeric proteins, UH-AH 37 interaction with muscarinic receptors and, 181
- Chloroquine, iron loading in liver and reticuloendothelial system and oxidative response by alveolar macrophages and, 907
- Chlorpromazine, platelet glycerolipid metabolism and, 1113
- Cholesterol, reducing, biochemical properties of SKP-450 in, 579
- Choline, levels in brain, *N*-methylnicotinamide influence on, 681
- Cholinergic neuronal system, modulation by dynorphin A (1–13), carbon monoxide-exposed mice, 1321
- Chrysene diphenols, mono- and diglucuronide formation from, by UDP-glycucuronosyltransferase isoforms, 653
- Cisplatin
- cellular sensitivity to, DNA mismatch repair and, 861
  - resistance to, excision repair cross complementation group 1 role in, 347
- Citalopram, apoptosis induced by, reactive oxygen species generation in mitochondrial membrane potential during, 1199
- c-Jun N-terminal kinase,  $\beta$ -lapachone suppression of, 763
- CL-387,785, epidermal growth factor receptors inhibition by, 917
- $\text{Cl}^-$  channels, inward current in *Xenopus* oocyte and, 491
- Clomipramine, apoptosis induced by, reactive oxygen species generation in mitochondrial membrane potential during, 1199
- Clostridium tetani*, sodium-dependent 5-HT inhibition and, in rat synaptosomes, 111
- Colon, cancer cells
- DNA damage to by oxidative stress-inducing agents, 19
  - naphthoquinones effects on, 27
- Copper, overexpression of, HeLa cell sensitivity to cisplatin and, 545
- Coronary heart disease, virgin olive oil effects in leukocytes and, 445
- Cosmeceutical, methyl gentisate evaluation as skin-lightening agent and, 663
- Cyclic AMP, signaling systems, serotonin-induced secretion of von Willebrand factor from umbilical vein endothelial cells via, 1191
- Cyclic nucleotide phosphodiesterase, inhibitors, immunomodulation and, 965
- Cycloheximide,  $\text{A}_{11}$ -induced cell death and, 97
- Cyclooxygenase, alminoprofen mechanisms of action and, 433
- CYP2A genes, expression in liver and extrahepatic tissues, 1407
- CYP2B2 gene, phenobarbital responsiveness of, 1073
- Cytochrome c oxidase II gene expression, suppression, adriamycin-induced cardiomyopathy and, 481
- Cytochrome P450
- hepatic, decrease in after interleukin-2 immunotherapy, 951
  - phenytoin role in wound healing and, 1085
  - reaction phenotyping of, 465
- Cytochrome P450 3A, midazolam, triazolam, and dexamethasone metabolism in liver microsomes and, mice, 1227
- Cytochrome P450 3A5 and 3A7, ethnic differences in expression frequency in hepatic samples, caucasian *vs.* Japanese subjects, 935
- Cytochrome P450 1B1, regulation in fibroblast cells by PKC, mice, 619

- Cytochrome P450 2E1, ethanol-inducible, [ $^3\text{H}$ ]norharman binding to, 511
- Cytosol, rat liver, acylfulvene metabolism in, 83
- Cytotoxic agents, cell death caused by, free-radical oxidative DNA damage and, 531
- Cytotoxicity
- cell, antiestrogen binding site and, 657
  - horseradish peroxidase and indole acetic acid, electrophilic oxidation products involved in, 375
  - hydrogen peroxide-induced, ebselen protective effects against, 273
- Daunomycin, apoptosis and NPM-translocation induced by, 1265
- Daunorubicin, antitumor effects, mechanisms of action of, 727
- Daunorubicin-GA3, distribution and pharmacokinetics in ovarian cancer xenografts, 673
- Defensins, epithelial peptide antibiotics and, 121
- Dehydroepiandrosterone sulfate, steroid functionality and, 329
- 15-Deoxyspergualin, selectivity of, 877
- Dexamethasone
- metabolism in liver microsomes, cytochrome P450 3A expression and, mice, 1227
  - pharmacologic characterization in bronchial epithelial cells, 1003
- Dextran
- binding on fibroblast growth factor 2 effects, 1399
  - trichosanthin immunogenicity lowering by coupling to, 927
- Dextrin sulfate, HIV-1 tat protein interaction with, 775
- DFMO: *see* DL- $\alpha$ -Difluoromethylornithine
- Diabetes, advanced glycation end products and, 303
- Diabetic hypertrophy, glycosphingolipid synthesis slowing as chemotherapeutic tool and, 589
- $\alpha,\beta$ -Dicarbonyl, PTB mechanism of action and, 303
- Diene, conjugated, fluvastatin sodium protective effects on oxidative modification of low-density lipoproteins and, 697
- Di-(2-ethylhexyl)phthalate, metabolism of phosphatidylethanolamine and phosphatidylcholine, in rat liver, 869
- DL- $\alpha$ -Difluoromethylornithine (DFMO), polyamine metabolism and, in African trypanosomes, 89
- Dihydrofolate reductase, glycinamide ribonucleotide formyltransferase inhibitor and trimetrexate, 567
- 1 $\alpha$ ,25-Dihydroxyvitamin D $_3$ , growth inhibition and differentiation in leukemia and, 521
- Diisopropyl phosphorofluoridate, mRNA expression of neurofilament subunits in brain and spinal cord after, hens, 1245
- DIM: *see* 2,3-Dimethoxy-1,4-Naphthoquinone
- 2,3-Dimethoxy-1,4-Naphthoquinone, colon cancer cell line effects, 27
- Dimethyl sulfoxide, calmodulin-stimulated ( $\text{Ca}^{2+}$ - $\text{Mg}^{2+}$ )-ATPase activity inhibition by, 39
- 3-(4-Dimethylamino-benzylidenyl)-2-indolinone, platelet-derived growth factor receptor inhibition and, 57
- Diphenylmethane, antiestrogen binding site and, 657
- Dissociation kinetics, allosteric modulation in muscarinic receptors and, 171
- DMBI: *see* 3-(4-Dimethylamino-benzylidenyl)-2-indolinone
- DMSO: *see* Dimethyl sulfoxide
- DNA binding
- estrogen receptors interaction with estrogen response elements and, 597
  - horseradish peroxidase and indole acetic acid cytotoxicity and, 375
- DNA damage
- in colon carcinoma cells by oxidative stress-inducing agents, 19
  - ebselen protective effects against, 273
  - free-radical oxidative, cell death by cytotoxic agents and, 531
- DNA mismatch repair, cellular sensitivity to cisplatin and, 861
- Docosahexanoic acid, protective effects against hydrogen peroxide-induced oxidative stress, 1021
- Dopamine receptors, functional activation in rat striatum, 155
- Drug metabolism
- cytochrome P450 and, reaction phenotyping of, 465
  - thiopene, toxicity in renal carcinoma cell lines, 1283
- Drug resistance
- acidic vesicle turnover and resistance to chemotherapeutic drugs and, 1047
  - cellular sensitivity to cisplatin, DNA mismatch repair and, 861
  - cisplatin, factors influencing, 347
  - gemcitabine, activity in ara-C-resistant leukemia cell lines, 397
  - membrane-associated P-glycoprotein and, 1037
- Dynorphin A (1–13), cholinergic neuronal system modulation by, carbon monoxide-exposed mice, 1321
- Ebselen, hydrogen peroxide-induced cytotoxicity and DNA damage effects, 273
- Eicosatetraenoic acid, prostaglandin H synthase inhibition and 12-lipoxygenase activation by, in endothelial cells and platelets, 631
- Electron paramagnetic resonance, nitric oxide levels in brain during ischemia-reperfusion, quercetin effects on, rats, 199
- Electropermeabilization, bleomycin internalization and, 45
- Elimination, ethanol, allometry model for prediction of, in mammals, 219
- Endocytosis, receptor-mediated, bleomycin internalization and, 45
- Endothelial cells
- dehydroepiandrosterone sulfate and, 329
  - vascular, activation by factor Xa, 603
- Enzymes, brain, 2-arachidonoylglycerol hydrolysis by, 417

- Epidermal growth factor  
extracellular signal-regulated protein kinase regulation, effects on mitogenesis, 425  
oxidant-induced barrier disruption inhibition in Caco-2 cells monolayers by, 685
- Epidermal growth factor receptors, inhibition with CL-387,785, 917
- Epithelial cells, bronchial, glucocorticoid receptor characterization in, 1003
- Epithelial peptide antibiotics, clinical studies of, 121
- Equilibrium binding studies, allosteric modulation in muscarinic receptors and, 171
- Escherichia coli*, exonuclease III mediation of phosphoglycolate removal in, 531
- Estrogen receptors, interaction with estrogen response elements, 597
- Estrogen response elements, estrogen receptors interaction with, 597
- Ethanol  
allometric model for predicting elimination of, in mammals, 219  
developmental neurotoxicity of, muscarinic cholinergic receptor signal transduction as target for, 721  
[<sup>3</sup>H]norharman binding to ethanol-inducible cytochrome P450 2E1 in liver and, 511  
prenatal biosynthesis of all-*trans*-retinoic acid inhibition by, 811  
sensitivity, molecular mechanisms of Fyn kinase to regulate behavior and, 845  
sex-dependent induction, rats, 1067  
in *utero* exposure to, muscarinic cholinergic receptor signal transduction and, 721
- 2-Ethoxyethanol, sex-dependent induction, rats, 1067
- Etoposide  
gemcitabine and, effects, non-small cell lung and ovarian cancer, 407  
intracellular localization of Bax protein and, 143
- Excision repair  
cisplatin-DNA adducts, enhancement by cell-free extract from cisplatin-resistant rat cell line, 1415  
cross complementation group 1, cisplatin resistance in ovarian cancer and, 347
- Excitation-contraction coupling, ryanodine receptor regulation by reactive nitrogen species and, 1079
- Exocytosis, of neutrophil granulocytes, 1209
- Exonuclease III, mediation of phosphoglycolate removal in *Escherichia coli*, 531
- FACS: *see* Fluorescence activated cell sorting
- Factor Xa, vascular endothelial cell activation by, 603
- Fatty acids  
 $\beta$ -oxidation and oxidative phosphorylation inhibition by NSAIDs and, 837  
oxygenation in platelets and endothelial cells, 631  
3-thia, as control site for ketogenesis, 1011
- <sup>59</sup>Fe-ferritin, mobilization evaluation of, 559
- Fenton reaction, iron deprivation as therapy and, 1345
- Fibroblast growth factor 2, dextran binding effects on, 1399
- Fluorescence activated cell sorting (FACS), TNF- $\alpha$  surface expression enhancement by matrix metalloprotease inhibitors and, 291
- Flurbiprofen,  $\beta$ -oxidation and oxidative phosphorylation inhibition by, 837
- Fluvastatin sodium, protective effects on oxidative modification of low-density lipoproteins, 697
- fMLP: *see* Formyl-methionyl-leucyl-phenylalanine
- Folic acid, synergy for trimetrexate and glycylamide ribonucleotide formyltransferase inhibitor, 567
- Formyl-methionyl-leucyl-phenylalanine (fMLP), phosphoinositide metabolism and calcium release and, piracetam effects and, 163
- Forskolin, P<sub>1</sub> receptors influence on effects of, in cyclic AMP accumulation and export in PC12 cells, 355
- Fyn kinase, behavior regulation and, molecular mechanisms of, ethanol sensitivity and, 845
- Gallamine, UH-AH 37 interaction with muscarinic receptors and, 181
- Gastric alcohol dehydrogenase, sex-dependent induction, rats, 1067
- Gastropathy, NSAIDs and, indomethacin and naproxen interaction, 247
- Gaucher's disease, glucosphingolipid synthesis slowing and, 589
- Geldanamycin, MAP kinase and, 281
- Gemcitabine  
activity in ara-C-resistant leukemia cell lines, 397  
etoposide and, effects, non-small cell lung and ovarian cancer, 407
- Gene therapy  
adenovirus attachment and internalization, receptors mediating, 975  
glial cell line-derived neurotrophic factor and, 135
- Genetic vectors, adenovirus attachment and internalization, receptors mediating, 975
- Gingival hyperplasia, phenytoin role in wound healing, 1085
- Glucocorticoid receptors, pharmacologic characterization in bronchial epithelial cells, 1003
- Glucose transport, regulation by IL-3 and oncogenes, 387
- Glucosphingolipid synthesis, slowing of, as chemotherapeutic tool, 589
- Glucuronidation, polycyclic aromatic hydrocarbon compounds induction of UDP-glycuronosyltransferase isoforms and, 653
- $\gamma$ -Glutamylcysteinylethyl ester, effects on selenium-deficient rat heart, 955
- Glutathione, biotransformation system mediated by, prostaglandin A<sub>2</sub> interaction with, 1383
- Glutathione homeostasis, tissue-specific regulation of, activator protein-1 response in rat conceptus and, 1165
- Glutathione peroxidase, selenium effects on thioredoxin reductase activity and, rats, 187
- Glycation end products, advanced, *N*-phenacylthiazolium

- bromide mechanism of action and, 303
- Glyceraldehyde, pancreatic  $\beta$ -cell function studies and, 583
- Glycerolipid metabolism, platelet, chlorpromazine and, 1113
- $\beta$ -Glycuronidase, daunorubicin-GA3 distribution and pharmacokinetics in ovarian cancer xenografts, 673
- Glyoxalase pathway, pancreatic  $\beta$ -cell function studies and, 583
- gp120 peptides, mechanism of anti-HIV activity of succinylated human serum albumin and, 889
- G-protein,  $\alpha$  subunit of, in splice variants in cardiac tissue, 539
- G-protein  $\beta\gamma$  subunit, mediation by opioid stimulation of adenylyl cyclase activity in olfactory bulb, rats, 649
- Growth factors: *see* specific type
- [ $^{35}$ S]-Guanosine 5'-O-( $\gamma$ -thiotriphosphate), dopamine receptor activation in rat striatum and, 155
- Guanylyl cyclase, isatin efficacy as antagonists of atrial natriuretic peptide receptors coupled to, 913
- Heart
- muscle, ryanodine receptor regulation by reactive nitrogen species and, 1079
  - oxidative phosphorylation inhibition and uncoupling by NSAIDs and, 743
  - tissue,  $G_s\alpha$  isoforms in, 539
- HeLa cells, copper, zinc-superoxide dismutase and catalase overexpression effects on sensitivity to *cis*-platinum, 545
- Hepatic alcohol dehydrogenase, sex-dependent induction, rats, 1067
- Hepatitis B virus, 3TC resistant, sensitivity to antiviral nucleoside analogues, 1351
- Hepatocellular carcinoma, asialoglycoprotein receptor expression in, DNA synthesis inhibitors toxicity and, 793
- Hepatocytes
- angiotensin II receptor internalization and signaling in, rats, 1125
  - time-dependent production of nitric oxide by, rats, 1223
- HepG<sub>2</sub> cells, ebselen protective effects against cytotoxicity and DNA damage in, 273
- Histamine, polyamines and, involvement in tumor growth, 1341
- Histamine H<sub>3</sub> receptor antagonists, effects, *tele*-methylhistamine levels, in rat cerebral cortex, 1059
- HIV: *see* Human immunodeficiency virus
- HIV-1: *see* Human immunodeficiency virus-1
- HIV protease inhibitors, P-glycoprotein inhibition and, 1147
- HIV-1 tat protein, interaction with sulphated polysaccharides, 775
- HMG-CoA reductase inhibitor, fluvastatin sodium protective effects on oxidative modification of low-density lipoproteins and, 697
- Horseradish peroxidase, indole-3-acetic acid and, electrophilic oxidation products in cytotoxicity of, 375
- Human immunodeficiency virus-1
- mechanism of anti-HIV activity of succinylated human serum albumin, 889
  - sulphated polysaccharides interaction with, 775
- Human immunodeficiency virus, chemokine receptors as therapy for, 451
- Hydrazine, methionine synthase activity effects, 1311
- Hydrogen peroxide
- chemically induced apoptosis of HL-60 cells, 1361
  - DNA damage in colon carcinoma cells and, 19
  - oxidative stress induced by, docosahexenoic acid protective effects against, 1021
- Hydrophobic agents, DMSO role in dissolution of, 39
- Hydroquinone, methyl gentisate evaluation as skin-lightening agent and, 663
- 6-Hydroxychrysene, mono- and diglucuronide formation from, by UDP-glyucuronosyltransferase isoforms, 653
- Hydroxyl radical, chemically induced apoptosis of HL-60 cells and, 1361
- Hydroxypyridinones
- blood-brain barrier permeability and, correlation between structure of, 1305
  - iron mobilization evaluation of, 559
- 5-Hydroxytryptamine, sodium-dependent, tetanus toxin inhibition by, in rat synaptosomes, 111
- Ibuprofen
- $\beta$ -oxidation and oxidative phosphorylation inhibition by, 837
  - up-regulation of IL-1 $\beta$  and TNF- $\alpha$  and, 313
- Illudin, acylfulvene metabolism in rat liver cytosol and, 83
- Imipramine, apoptosis induced by, reactive oxygen species generation in mitochondrial membrane potential during, 1199
- Immune function, NF- $\kappa$ B/Rel proteins and, 1
- Immunity, innate, epithelial peptide antibiotics and, 121
- Immunogenicity, trichosanthin, lowering by coupling to dextran, 927
- Immunomodulation, cyclic nucleotide phosphodiesterase inhibitors and, 965
- Immunoregulatory proteins, chemokine receptors, HIV therapy and, 451
- Immunosuppression, glucosphingolipid synthesis slowing as chemotherapeutic tool and, 589
- Immunosuppressive agents, 15-deoxyspergualin, selectivity of, 877
- Immunotherapy, interleukin-2, hepatic cytochrome P450 levels after, 951
- Indole acetic acid, horseradish peroxidase and, electrophilic oxidation products in cytotoxicity of, 375
- Indomethacin, naproxen and, gastric toxicity of NSAIDs and, 247
- Infectious disease, iron deprivation as therapy and, 1345
- Inflammatory response, lipopolysaccharide-induced, bactericidal/permeability-increasing protein effects on, 225
- Inhibitor- $\kappa$ B $\alpha$ , ibuprofen inhibition of, 313
- INS-1D cells, alloxan-exposed, insulin release modulation

- in, 639
- Insulin release
- pancreatic islet, inhibition by somatostatin analogs, 1159
  - trioses in pancreatic  $\beta$ -cell function studies and, 583
- Insulin secretion, modulation in INS-1 cells exposed to alloxan, 639
- Interleukin-1 $\beta$
- atypical PKC isoform role in NF- $\kappa$ B activation by, 713
  - ibuprofen effects on up-regulation of, 313
- Interleukin-3, glucose transport regulation by, 387
- Interleukin-2, immunotherapy, hepatic cytochrome P450 levels after, 951
- Intestine, oxidant-induced barrier disruption inhibition in Caco-2 cells monolayers by epidermal growth factor and, 685
- Iron chelators
- blood-brain barrier permeability and, correlation between structure of, 1305
  - efficacy of, mobilization evaluation for testing, 559
  - zinc-finger domains and, 1031
- Iron deprivation, role in muscle necrosis in myopathy, 1345
- Iron loading, chloroquine effects on in liver and reticuloendothelial system, 907
- Iron uptake, by U-937 cells, ascorbic acid role in, 1275
- Isatin, efficacy as antagonists of atrial natriuretic peptide receptors coupled guanylyl cyclase, 913
- Ischemia-reperfusion
- iron deprivation as therapy and, 1345
  - myocardial, schisandrin role in protection against, rats, 77
  - quercetin influence on nitric oxide level in brain during, rats, 199
- Isoprenylation, inhibition by limonene, 801
- Ketogenesis, 3-thia fatty acids and carnitine palmitoyltransferase II as control sites for, 1011
- Ketorolac,  $\beta$ -oxidation and oxidative phosphorylation inhibition by, 837
- Kojic acid, methyl gentisate evaluation as skin-lightening agent and, 663
- L1210 cells,  $N^8$ -acetylspermidine deacetylase inhibition effects on, 1095
- $\beta$ -Lapachone, suppression of TNF $\alpha$ -activated NF- $\kappa$ B, activator protein-1, c-Jun N-terminal kinase, and apoptosis, 763
- Leukemia, growth inhibition and differentiation in, retinoid receptors effects on, 521
- Limonene, protein prenylation inhibition by, 801
- Lipid metabolism, inositol, phosphoinositide effects in, breast epithelial cancer cell lines, 1153
- Lipid peroxidation
- fluvastatin sodium protective effects on oxidative modification of low-density lipoproteins and, 697
  - horseradish peroxidase and indole acetic acid cytotoxicity and, 375
  - prenatal biosynthesis of all-*trans*-retinoic acid inhibition by, 811
- Lipoamine dehydrogenase, enzymatic reduction studies of nitroheterocycles and, 549
- Lipopolysaccharides, inflammatory properties of, Gram-negative bacterial infections and, 225
- Lipoproteins
- lectin-like oxidized low-density, expression on vascular smooth muscle cells, lovastatin effects on, 383
  - low-density, fluvastatin sodium protective effects on oxidative modification of, 697
- 12-Lipoxygenase, activation by eicosatetraenoic acid, 631
- Liver
- chloroquine effects on iron loading in, 907
  - CYP2A gene expression in, 1407
  - [ $^3$ H]norharman binding to ethanol-inducible cytochrome P450 2E1 in, 511
- Lovastatin, oxidized low-density lipoprotein receptor expression on vascular smooth muscle cells and, 383
- Lung cancer, non-small cell, gemcitabine and etoposide effects in, 407
- Macrophages
- cytokine expression in, quercetin and resveratrol effects on, 941
  - platelet-activating factor receptor increase in, 263
- Macrovascular disease, advanced glycation end products and, 303
- Magnesium ascorbylphosphate, methyl gentisate evaluation as skin-lightening agent and, 663
- Magnetic resonance spectroscopy, tumor pH in breast cancer xenografts, 309
- Malaria, primaquine induction of cytochrome 1A1 in hepatocytes and, 255
- MAP kinase: see Mitogen-activated protein kinase
- Matrix metalloprotease inhibitors, TNF- $\alpha$  surface expression and, 291
- MCF-7 cells, adriamycin- and benzo[ $\alpha$ ]pyrene-resistant, Ah receptor loss in, 1253
- Melanogenesis, methyl gentisate, evaluation as skin-lightening agent, 663
- Melittin, alminoprofen mechanisms of action and, 433
- Membrane, oxatamide influence on, 503
- MEN: see Menadione
- Menadione
- colon cancer cell line effects, 27
  - DNA damage in colon carcinoma cells and, 19
- Metal transcription factor-1, zinc affinity and, 1031
- 2-Methoxyethanol, sex-dependent induction, rats, 1067
- Methyl gentisate, evaluation as skin-lightening agent, 663
- Methylglyoxal, pancreatic  $\beta$ -cell function studies and, 583
- tele-Methylhistamine levels, histamine H $_3$  receptor antagonists effects on, in rat cerebral cortex, 1059
- N-Methylnicotinamide, formation in brain from dihydropyridine-type prodrug, 681
- Microtubule, paclitaxel-induced apoptosis and, 1215
- Midazolam, metabolism in liver microsomes, cytochrome

- P450 3A expression and, mice, 1227
- Mitochondria, oxidative phosphorylation inhibition and uncoupling by NSAIDs and, 743
- Mitochondrial membrane potential, reactive oxygen species generation in, durign antidepressant-induced apoptosis, 1199
- Mitochondrial  $\beta$ -oxidation, oxidative phosphorylation and, inhibition by NSAIDs and, 837
- Mitogen-activated protein kinase (MAP kinase), tyrphostin and geldanamycins effects on, 281
- Mitogenesis, epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase and, 425
- Mitotic arrest, paclitaxel-induced apoptosis and, 1215
- Molecular chaperone, 15-deoxyspergualin, selectivity of, 877
- Monofluoromethylhistidine, histamine and polyamines involvement in tumor growth and, 1341
- Monoterpenes, limonene, protein prenylation inhibition by, 801
- MRS: *see* Magnetic resonance spectroscopy
- Multidrug resistance (MDR)
- acidic vesicle turnover and resistance to chemotherapeutic drugs and, 1047
  - glucosphingolipid synthesis slowing as chemotherapeutic tool and, 589
  - membrane-associated P-glycoprotein and, 1037
  - proteins, sister of P-glycoprotein, expression in different tissues, 833
- Muscarinic receptors
- allosteric modulator subtype selectivity characterization at, 171
  - developmental neurotoxicity of ethanol and, 721
  - UH-AH 37 interaction with, 181
- Myocardial ischemia-reperfusion, schisandrin molecule role in protection against, rats, 77
- Myopathy, muscle necrosis in, iron deprivation role in therapy for, 1345
- $N^8$ -Acetylspermidine deacetylase, inhibition effects on L1210 cells, 1095
- 1,4-Naphthoquinone, colon cancer cell line effects, 27
- Naphthoquinones, colon cancer cell line effects, 27
- Naproxen, indomethacin and, gastric toxicity of NSAIDs and, 247
- Necrosis, reactive oxygen intermediates as mediators of programmed cell death and, 231
- N*-Ethylmaleimide, arachidonic acid release in platelets and, 785
- Neuronal cell death, glial cell line-derived neurotrophic factor gene therapy and, 135
- Neuronal dysfunction, signaling pathways in, 1
- Neurotensin,  $\beta$ -adrenergic agonist and, effects on cAMP accumulation and DNA synthesis in prostate cancer, 1391
- Neurotoxicity, developmental, *in utero* exposure to ethanol and, 721
- Neurotrophic factor, glial cell line-derived, gene therapy role, 135
- Neutrophil granulocytes, exocytosis of, 1209
- NF- $\kappa$ B: *see* Nuclear factor- $\kappa$ B
- NF- $\kappa$ B/Rel proteins
- cancer treatment and, 9
  - signaling pathways in neuronal dysfunction, 1
- Nifedipine oxidation activity, cytochrome P450 3A5 and 3A7, ethnic differences in expression frequency in hepatic samples, caucasian vs. Japanese, 935
- Nitric oxide
- tert*-butyl hydroperoxide/hemoglobin-induced oxidative stress and, effects on vascular smooth muscle cells, 989
  - quercetin effects on level in brain during ischemia-reperfusion, rats, 199
  - synthase, ryanodine receptor regulation by reactive nitrogen species and, 1079
  - time-dependent production by hepatocyte suspensions, rats, 1223
  - tripyrindine-induced generation in macrophages, tyrosine kinase role in, 1367
- Nitro anion radical, enzymatic reduction studies of, 549
- Nitroheterocycle, enzymatic reduction studies of, 549
- NK<sub>2</sub> receptor, tyrosine/phenylalanine mutation effects on, 899
- Nonsteroidal anti-inflammatory drugs
- alminoprofen, mechanisms of action of, 433
  - gastric toxicity of, indomethacin and naproxen interaction and, 247
  - ibuprofen pharmacokinetics, 313
  - $\beta$ -oxidation and oxidative phosphorylation inhibition by, 837
  - oxidative phosphorylation inhibition and uncoupling by, 743
- [<sup>3</sup>H]Norharman, binding to ethanol-inducible cytochrome P450 2E1, 511
- NPM-translocation, apoptosis and, daunomycin effects on, 1265
- NQ: *see* 1,4-Naphthoquinone
- NSAIDs: *see* Nonsteroidal anti-inflammatory drugs
- Nuclear factor- $\kappa$ B
- ibuprofen inhibition of, 313
  - $\beta$ -lapachone suppression of, 763
- Nuclear magnetic resonance, ubiquitin reaction with aspirin, 1233
- Nuclear translocator, aryl hydrocarbon receptor, activation and repression domains of, rainbow trout, 1177
- Olfactory bulb, G protein  $\beta\gamma$  subunit mediation by opioid stimulation of adenylyl cyclase activity, rats, 649
- Olive oil, virgin, anti-eicosanoid/antioxidant effects in leukocytes, 445
- Oncogenes, glucose transport regulation by, 387
- Opioid receptors, G protein  $\beta\gamma$  subunit mediation by, in olfactory bulb, rats, 649
- Ornithine decarboxylase, histamine and polyamines involvement in tumor growth and, 1341

- Ovarian cancer  
 cisplatin-based chemotherapy, resistance to, excision repair cross complementation group 1 and, 347  
 gemcitabine and etoposide effects in, 407  
 tetrazepione mechanism of action in, 753  
 xenografts, daunorubicin-GA3 distribution and pharmacokinetics in, 673
- Oxatomide, influence on membrane structures, 503
- $\beta$ -Oxidation, oxidative phosphorylation and, inhibition by NSAIDs and, 837
- Oxidation, retinal, liver cytosolic aldehyde dehydrogenase role in, 195
- Oxidative burst, reactive oxygen intermediates as mediators of programmed cell death and, 231
- Oxidative phosphorylation, inhibition and uncoupling by NSAIDs, 743
- Oxidative response, chloroquine administration effects on, in alveolar macrophages, 907
- Oxidative stress  
 apoptosis induced by, ascorbic acid role in inhibition of, in leukemia cells, 823  
 hydrogen peroxide-induced, docosahexanoic acid protective effects against, 1021
- Oxygen metabolism, enzymatic reduction studies of nitroheterocycles, 549
- Oxygen radicals, zymosan-induced, resveratrol inhibitory effects on, 705
- $P_1$  receptors, forskolin effects in cyclic AMP accumulation and export in PC12 cells and, 355
- Paclitaxel, apoptosis induced by, mechanisms of, 1215
- Pancreatic  $\beta$ -cells, trioses for study of, 583
- Pancreatic islets, insulin release, inhibition by somatostatin analogs, 1159
- Parkinson's disease  
 glial cell line-derived neurotrophic factor gene therapy and, 135  
 NF- $\kappa$ B/Rel protein role in signaling pathways in, 1
- PC12 cells  
 adenosine  $A_{2A}$  receptor differences in, human *vs.* rat, 65  
 $P_1$  receptors influence on forskolin effects in cyclic AMP accumulation and export in PC12 cells, 355
- Peptidyl dipeptidase, structure-function studies of *N*-acetylseryl-aspartyl-lysyl-proline and, 611
- P-Glycoprotein  
 membrane-associated, multidrug resistance and, 1037  
 ritonavir inhibition and, 1147  
 sister of, expression in different tissues, 833
- Pharmacokinetics, allometric model for predicting blood ethanol elimination, in mammals, 219
- N*-Phenacetylthiazolium bromide (PTB), mechanism of action of, 303
- Phenobarbital response unit, CYP2B2 gene and, 1073
- Phenothiazine pharmacology, chlorpromazine and platelet glycerolipid metabolism, 1113
- Phenytoin  
 hydroxylation in Japanese, chiral preference of CYP2C9 and CYP2C19, 1297  
 wound healing role, 1085
- Phosphatidylcholine, tiadenol and di-(2-ethylhexyl)phthalate effects on metabolism of, in rat liver, 869
- Phosphatidylethanolamine, tiadenol and di-(2-ethylhexyl)phthalate effects on metabolism of, in rat liver, 869
- Phosphodiesterase 4 isoforms, characterization and evaluation of, 1375
- Phosphoglycolate, exonuclease III mediation of removal of, in *Escherichia coli*, 531
- Phospholipase  $A_2$ , alminoprofen mechanisms of action and, 433
- Phosphoinositide, inositol lipid metabolism in breast epithelial cancer cell lines, 1153
- Pigmentation, methyl gentisate evaluation as skin-lightening agent and, 663
- Piracetam, polyphosphoinositide metabolism, calcium release, and oxidative burst in polymorphonuclear cells and, 163
- Plasminogen activatory inhibitor-1, vascular endothelial cell activation by factor Xa and, 603
- Platelet aggregation, ADP-induced, adenyl cyclase activity inhibition, prostaglandins and, 851
- Platelet-activating factor, receptors, increase in platelets and macrophages, 263
- Platelet-derived growth factor receptor, tyrosine kinase activity, DMBI as inhibitor of, 57
- Platelets  
*N*-ethylmaleimide-stimulated arachidonic acid release in, 785  
 platelet-activating factor receptor increase in, 263
- Polyamine synthesis, methylthioadenosine phosphorylase substrate analog effects on, 89
- Polyamines, histamine and, involvement in tumor growth, 1341
- Polyanion, mechanism of anti-HIV activity of succinylated human serum albumin and, 889
- Polymerase chain reaction, sister of P-glycoprotein expression in different tissues, 833
- Polymorphonuclear leukocyte, piracetam action on, 163
- Polysaccharides, sulphated, HIV-1 tat protein interaction with, 775
- Primaquine  
 cytochrome 1A1 induction in hepatocytes and, malaria effects, 255  
 cytochrome 1A1 induction in hepatocytes and HepG2 cells, 255
- Proliferation, vascular endothelial cell activation by factor Xa and, 603
- Propranolol, chlorpromazine and glycerolipid metabolism and, 1113
- Prostaglandin  $A_2$ , interaction with glutathione-mediated biotransformation system, 1383
- Prostaglandin H synthase, inhibition by eicosatetraenoic acid, 631

- Prostate cancer, neurotensin and  $\beta$ -adrenergic agonist effects on cAMP accumulation and DNA synthesis in, 1391
- Protein kinase, mitogen-activated: *see* Mitogen-activated protein kinase
- Protein kinase C  
atypical isoforms, role, NF- $\kappa$ B activation by IL-1 $\beta$  or TNF $\alpha$ , 713  
cytochrome P4501B1 regulation in fibroblast cells by, mice, 619
- Protein phosphatase 2A, regulation of, 321
- Protein prenylation, inhibition by limonene, 801
- Protein:farnesyl transferase, smooth muscle cell inhibition and, 365
- PTB: *see* *N*-phenacylthiazolium bromide
- Quercetin  
nitric oxide level in brain during ischemia-reperfusion injury, rats, 199  
resveratrol, effects, cytokine expression in RAW 264.7 macrophages, 941
- Quinones, in colon cancer cell lines, 27
- Ras, glucose transport regulation by IL-3 and oncogenes and, 387
- Reaction phenotyping, cytochrome P450 and, 465
- Reactive nitrogen species, ryanodine receptor regulation by, 1079
- Reactive oxygen intermediates, programmed cell death and, 231
- Reactive oxygen species  
antioxidants and, 273  
copper, zinc-superoxide dismutase, and catalase overexpression effects on HeLa cell sensitivity to *cis*-platinum and, 545  
generation in mitochondrial membrane potential during antidepressant-induced apoptosis, 1199  
iron deprivation as therapy and, 1345  
production inhibitor, resveratrol effects as, 705
- Renal cancer, thiopene toxicity in, 1283
- Renal insufficiency, advanced glycation end products and, 303
- Resveratrol  
inhibitory effects on zymosan-induced oxygen radical production, 705  
quercetin and, effects, cytokine expression in RAW 264.7 macrophages, 941
- Reticuloendothelial system, chloroquine effects on iron loading in, 907
- Retinal oxidation, liver cytosolic aldehyde dehydrogenase role in, 195
- Retinoic acid, synthesis, liver cytosolic aldehyde dehydrogenase role in, 195
- Retinoic acid receptors, growth inhibition and differentiation in leukemia and, 521
- Retinoid receptors, growth inhibition and differentiation in leukemia and, 521
- Retinoid X receptor, growth inhibition and differentiation in leukemia and, 521
- Ritonavir, P-glycoprotein inhibition and, 1147
- Rosmarinic acid, complement inhibition by attachment to activated C3b, 1439
- Ruthenium red, adrenal glomerulosa cell inhibition by, rat, 209
- Ryanodine receptors, regulation by reactive nitrogen species, 1079
- S-adenosylmethionine metabolism, trypanosomiasis and, 89
- Scavenger receptor, lovastatin effects on oxidized low-density lipoprotein receptor expression on vascular smooth muscle cells and, 383
- SCH 37370, increase in platelets and macrophages, 263
- Schisandrin, myocardial ischemia-reperfusion injury protection and, rats, 77
- Se-glutathione peroxidase, schisandrin role in protection against myocardial ischemia-reperfusion injury and, rats, 77
- Selenium  
deficiency in heart,  $\gamma$ -glutamylcysteinylethyl ester effects on, 955  
thioredoxin reductase activity and, rats, 187
- Serum steroids, dehydroepiandrosterone sulfate and, 329
- Signal transduction, NF- $\kappa$ B/Rel proteins in cancer treatment and, 9
- Signaling pathways, in neuronal function and dysfunction, NF- $\kappa$ B/Rel proteins and, 1
- Sister of P-glycoprotein, expression in different tissues, 833
- Skatolyl radical, horseradish peroxidase and indole acetic acid cytotoxicity and, 375
- Skeletal muscle, ryanodine receptor regulation by reactive nitrogen species and, 1079
- Skin-lightening agents, methyl gentisate, evaluation of, 663
- SKP-450, biochemical basis for cholesterol-lowering properties, 579
- Small t antigen, protein phosphatase 2A regulation and, 321
- Smooth muscle cells  
protein:farnesyl transferase inhibition of, 365  
inhibition by taurine, rats, 1331  
oxidized low-density lipoprotein receptor expression on, lovastatin effects on, 383  
*tert*-butyl hydroperoxide/hemoglobin-induced oxidative stress effects on, 989
- Somatostatin analogs, pancreatic islet insulin release inhibition by, 1159
- Sphingolipidoses, glucosphingolipid synthesis slowing and, 589
- Spinal cord, mRNA expression of neurofilament subunits in, diisopropyl phosphorofluoridate-treated hens, 1245
- Squalene synthase, farnesyl pyrophosphate role in inhibition of, 365
- Stem cells, structure-function studies of *N*-acetyl-seryl-

- aspartyl-lysyl-proline and, 611
- Striatum, dopamine receptor activation in, rats, 155
- Succinylated human serum albumin, mechanism of anti-HIV activity of, 889
- Sugar moiety, pharmacologic activity of anthracycline disaccharides and, 1133
- Tamoxifen, antiestrogen binding site and, 657
- Taurine, vascular smooth muscle cell inhibition by, 1331
- TCDD: *see* 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
- Testosterone, steroid functionality and, 329
- Tetanus toxin, sodium-dependent 5-HT inhibition by, in rat synaptosomes, 111
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD), cytochrome P4501B1 regulation in fibroblast cells and, mice, 619
- 12-O-Tetradecanoylphorbol-13-acetate (TPA), cytochrome P4501B1 regulation in fibroblast cells and, mice, 619
- Tetrahydrowertianolin, inhibitory effects on TNF $\alpha$ -dependent hepatic apoptosis, mice, 1431
- Tetrazepione, mechanism of action in ovarian cancer cell line, 753
- 3-Thia fatty acids, as control site for ketogenesis, 1011
- Thiazolium, PTB mechanism of action and, 303
- Thiopene, toxicity in renal carcinoma cell lines, 1283
- Thioredoxin reductase, selenium effects on, rat, 187
- Thymosin  $\beta_4$ , apoptosis induced by antitumor drugs and, 1105
- Tiadenol, metabolism of phosphatidylethanolamine and phosphatidylcholine, in rat liver, 869
- Tissue plasminogen activator, vascular endothelial cell activation by factor Xa and, 603
- TNF: *see* Tumor necrosis factor
- Topoisomerase II, inhibition by aporphine alkaloids, 1141
- Tor, protein phosphatase 2A regulation and, 321
- TPA: *see* 12-O-Tetradecanoylphorbol-13-acetate
- Transcription factors, NF- $\kappa$ B/Rel proteins, cancer treatment and, 9
- Triazolam, metabolism in liver microsomes, cytochrome P450 3A expression and, mice, 1227
- Trichosanthin, immunogenicity, lowering by coupling to dextran, 927
- Trimetrexate, glycinamide ribonucleotide formyltransferase inhibitor and, 567
- Trioses, pancreatic  $\beta$ -cell function studies and, 583
- Trypanosomiasis, African, methylthioadenosine phosphorylase substrate analog effects on, 89
- Trypanothione reductase, enzymatic reduction studies of nitroheterocycles and, 549
- Tryphostin, MAP kinase and, 281
- Tumor growth, histamine and polyamines involvement in, 1341
- Tumor necrosis factor- $\alpha$
- atypical PKC isoform role in NF- $\kappa$ B activation by, 713
  - hepatic apoptosis, tetrahydrowertianolin inhibitory effects, mice, 1431
  - ibuprofen effects on up-regulation of, 313
  - $\beta$ -lapachone suppression of, 763
  - surface expression enhancement by matrix metalloproteinase inhibitors and, 291
- Tumor pH, in breast cancer xenografts, MRS investigation of, 309
- Tyrosinase-related proteins, methyl gentisate evaluation as skin-lightening agent and, 663
- Tyrosine kinase
- activity, PDGFR, DMBI as inhibitor of, 57
  - inhibition by CL-387,785, 917
  - tripyrindine-induced nitric oxide generation in macrophages and, 1367
- Tyrosine/phenylalanine mutation, effects on tachykinin NK $_2$  receptor, 899
- U-937 cells, iron uptake and reduction by, ascorbic acid role in, 1275
- Ubiquitin, reaction with aspirin, NMR analysis, 1233
- UH-AH 37, interaction with muscarinic receptors, 181
- V3 loop peptides, mechanism of anti-HIV activity of succinylated human serum albumin and, 889
- Viral vectors, adenovirus attachment and internalization, receptors mediating, 975
- Vitamin D $_3$ , growth inhibition and differentiation in leukemia and, 521
- von Willebrand factor, serotonin-induced secretion of, from umbilical vein endothelial cells via cyclic AMP-signaling systems, 1191
- Wound healing, phenytoin role in, 1085
- Xenobiotic metabolism, CYP2A gene expression in liver and extrahepatic tissues and, 1407
- Xenopus* oocyte, Ca $^{2+}$  entry and Cl $^{-}$  exit and, 491
- Zinc, iron chelators and zinc-finger domains for, 1031
- Zinc-superoxide dismutase, overexpression of, HeLa cell sensitivity to *cis*-platinum and, 545
- Zymosan, unopsonized, as reactive oxygen species production inhibitor, 705